MS drug in breastmilk: new study checks baby safety
NCT ID NCT04998851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how much of the multiple sclerosis drug ocrelizumab gets into breastmilk and whether it affects babies' immune cells. Twenty-six breastfeeding mothers with MS or clinically isolated syndrome took part. Researchers measured drug levels in breastmilk and checked B cell counts in their infants after the mothers received their first postpartum dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab
What this could lead to
If successful, this study could help doctors understand whether it is safe for mothers with MS to breastfeed while taking ocrelizumab.
What could go wrong
This is a small, completed study with only 26 participants, so results may not apply to all mothers. It only measured short-term effects on infants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Womens Hospital
Boston, Massachusetts, 02115, United States
-
Hosp. Clinico San Carlos
Madrid, 28040, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
Owosso, Michigan, 48867, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611-2987, United States
-
Queen Mary University of London
London, EC1M 6BQ, United Kingdom
-
University Of Colorado
Aurora, Colorado, 80045, United States
-
University of California San Francisco
San Francisco, California, 94158, United States